Reduction of imiquimod impurities in pharmaceutical creams

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7928118
APP PUB NO 20100130532A1
SERIAL NO

12698113

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
MEDICIS PHARMACEUTICAL CORPORATIONSCOTTSDALE, AZ112

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Nelson, Robert J Cottage Grove, US 92 2517
Statham, Alexis S Woodbury, US 36 602

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
2003/0026,794 Selective enzyme treatment of skin conditions 39 2001
2003/0059,471 Oral delivery formulation 120 2001
 
MINNESOTA MINING AND MANUFACTURING COMPANY (2)
4411893 Topical medicament preparations 75 1982
5346905 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines 247 1992
 
KYTHERA BIOPHARMACEUTICALS, INC. (1)
2005/0201,959 Methods and compositions for altering skin coloration 31 2004
 
ALZA CORPORATION (2)
4746515 Skin permeation enhancer compositions using glycerol monolaurate 111 1987
6210712 Dosage form having first and second coats 61 1998
 
THERATECH, INC. (1)
4863970 Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols 205 1988
 
PERICOR SCIENCE, INC. (1)
6267957 Attaching agents to tissue with transglutaminase and a transglutaminase substrate 89 1999
 
GRACEWAY PHARMACEUTICALS, LLC (2)
4689338 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use 345 1985
5238944 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine 254 1992
 
LUITPOLD PHARMACEUTICALS, INC. (1)
5919815 Taxane compounds and compositions 110 1996
 
MEPHA AG (1)
2006/0039,931 Stable cream preparations of phenyl-pyridone compounds for topical application 34 2003
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (1)
6194425 Imidazonaphthyridines 196 1998
 
CORIUM INTERNATIONAL, INC. (2)
6803420 Two-phase, water-absorbent bioadhesive composition 90 2002
2003/0170,308 Hydrogel compositions 99 2002
 
FUJIMORI KOGYO CO., LTD. (1)
4686125 Film laminate for sterile flexible containers 105 1984
 
Noven Pharmaceuticals, Inc. (3)
5300291 Method and device for the release of drugs to the skin 94 1991
6562363 Bioadhesive compositions and methods for topical administration of active agents 178 1998
6638528 Compositions and methods to effect the release profile in the transdermal administration of active agents 126 2002
 
COLEY PHARMACEUTICAL GROUP, INC. (10)
5268376 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines 250 1991
5266575 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines 245 1991
5352784 Fused cycloalkylimidazopyridines 244 1993
5446153 Intermediates for imidazo[4,5-c]pyridin-4-amines 208 1994
5482936 Imidazo[4,5-C]quinoline amines 222 1995
6376669 Dye labeled imidazoquinoline compounds 178 2000
6660735 Urea substituted imidazoquinoline ethers 146 2002
6677347 Sulfonamido ether substituted imidazoquinolines 141 2002
6677348 Aryl ether substituted imidazoquinolines 141 2002
2004/0176,367 1-Amino 1H-imidazoquinolines 88 2004
 
ABB TECHNOLOGY AG (1)
2004/0089,855 High oleic acid oil compositions and methods of making and electrical insulation fluids and devices comprising the same 33 2003
 
GALENIX INNOVATIONS (2)
2003/0096,012 Film-forming powder, compositions containing it, methods for their preparation and their uses 66 2002
2003/0124,191 Use of an immediate-release powder in pharmaceutical and nutraceutical compositions 63 2002
 
HENKEL IP & HOLDING GMBH (1)
2002/0128,345 Hot melt adhesives for dermal application 39 2000
 
INTERCONNECTRON GMBH (1)
6425776 Circular plug and socket connector for producing electrical line connections 33 2000
 
AGIS INDUSTRIES LTD. (1)
2006/0034,779 Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same 34 2005
 
REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE (1)
2005/0175,630 Immunogenic compositions and methods of use thereof 48 2004
 
ASTRA AKTIEBOLAG (1)
6103697 Peptides with immunomodulatory effects 35 1997
 
3M INNOVATIVE PROPERTIES COMPANY (25)
6039969 Immune response modifier compounds for treatment of TH2 mediated and related diseases 236 1997
6110929 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 202 1999
6245776 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier 231 2000
6200592 Immine response modifier compounds for treatment of TH2 mediated and related diseases 107 2000
6331539 Sulfonamide and sulfamide substituted imidazoquinolines 194 2000
6451810 Amide substituted imidazoquinolines 172 2000
6656938 Urea substituted imidazoquinoline ethers 147 2001
6660747 Amido ether substituted imidazoquinolines 142 2001
6664260 Heterocyclic ether substituted imidazoquinolines 136 2001
6664264 Thioether substituted imidazoquinolines 147 2001
6670372 Aryl ether substituted imidazoquinolines 141 2001
6683088 Sulfonamido ether substituted imidazoquinolines 141 2001
6756382 Amide substituted imidazoquinolines 114 2001
6525064 Sulfonamido substituted imidazopyridines 164 2002
6545016 Amide substituted imidazopyridines 160 2002
6545017 Urea substituted imidazopyridines 161 2002
6664265 Amido ether substituted imidazoquinolines 147 2002
6667312 Thioether substituted imidazoquinolines 146 2002
2003/0199,538 Pharmaceutical formulation comprising an immune response modifier 110 2002
6677349 Sulfonamide and sulfamide substituted imidazoquinolines 143 2003
6797718 Ether substituted imidazopyridines 111 2003
2004/0091,491 Immunostimulatory compositions and methods of stimulating an immune response 99 2003
6818650 1H-imidazo dimers 111 2003
2004/0132,766 1H-imidazo dimers 56 2003
2004/0147,543 Aryl substituted imidazoquinolines 92 2003
 
CRESCITA THERAPEUTICS INC. (1)
2005/0276,842 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same 69 2005
 
Nippon Oil and Fats Co., Ltd. (1)
4601856 Method of purifying oleic acid 35 1985
 
MEDICIS PHARMACEUTICAL CORPORATION (7)
5389640 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 272 1992
5736553 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo?4,5-C!quinolin-4-amine 68 1995
5939090 Gel formulations for topical drug delivery 197 1996
6541485 Urea substituted imidazoquinolines 155 2000
6573273 Urea substituted imidazoquinolines 149 2001
2004/0192,585 Treatment for basal cell carcinoma 84 2004
2007/0167,479 Immune response modifier formulations and methods 57 2005
 
The Procter & Gamble Company (1)
5008110 Storage-stable transdermal patch 113 1988
 
WARNER-LAMBERT COMPANY (1)
4908389 Penetration enhancement system 58 1986
 
SHISEIDO COMPANY, LTD. (1)
5472982 Emulsified external treatment composition containing diclofenac sodium 31 1993
 
Riker Laboratories, Inc. (4)
4751087 Transdermal nitroglycerin delivery system 96 1985
4698348 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents 278 1985
4929624 Olefinic 1H-imidazo(4,5-c)quinolin-4-amines 284 1989
5756747 1H-imidazo?4,5-c!quinolin-4-amines 207 1995
 
COGNIS CORPORATION (1)
6498261 Process for improving color and color stability of oleic acid 31 1995
 
DERMATRENDS, INC. (1)
2003/0072,814 Topical pharmaceutical composition for the treatment of warts 94 2002
 
LTS LOHMANN THERAPIE-SYSTEME AG (1)
7056528 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin 34 2000
 
Hisamitsu Pharmaceuticals (1)
7504114 Preparations for percutaneous absorption 35 2000
 
Purcell Jojoba International, LLC (1)
6559182 Method for treatment of enveloped viruses using jojoba oil esters 33 2001
 
VIRUN, INC. (1)
2005/0281,772 Compositions for mucosal delivery of agents 64 2005
 
PERRIGO ISRAEL PHARMACEUTICALS LTD. (1)
2006/0024,243 Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same 31 2005
 
RANBAXY LABORATORIES LIMITED (1)
2005/0037,030 Stable topical formulation of clarithromycin 30 2004
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4695465 Soft patch 124 1985
 
A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESES, RUSSIAN ACADEMY OF SCIENCES (1)
2004/0242,770 Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith 70 2004
 
PHARMACIA & UPJOHN COMPANY (1)
2003/0211,163 Combination antiviral therapy 37 2003
 
MITSUI CHEMICALS, INC. (1)
5532030 Polyolefin multilayer laminate, vessel and packaging material 69 1995
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
MEDICIS PHARMACEUTICAL CORPORATION (6)
* 2010/0160,368 Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy 5 2009
* 2011/0207,766 LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS 1 2010
8598196 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2012
8642616 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 0 2012
9271973 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2013
9078889 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 1 2013
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Oct 19, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 19, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00